Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

620
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
620
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

1.1K
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
1.1K
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

3.3K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
3.3K
Asthma-IV: Nursing Management01:30

Asthma-IV: Nursing Management

4.0K
The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...
4.0K
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

627
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
627
Chronic Obstructive Pulmonary Disease-V: Nursing Management01:30

Chronic Obstructive Pulmonary Disease-V: Nursing Management

5.5K
Nursing management of Chronic Obstructive Pulmonary Disease (COPD) is crucial for providing thorough care and support to patients. Nurses play an integral role in this process through detailed assessment, careful planning, targeted interventions, and ongoing evaluation. Here's an overview of the critical steps in nursing management for COPD.
Assessment
5.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Epidemiology of Alpha-1 Antitrypsin Deficiency in the Veterans Health Administration.

Annals of the American Thoracic Society·2025
Same author

Inhaled alpha-1 antitrypsin (AAT) restores lower respiratory tract protease-antiprotease homoeostasis and reduces inflammation in AAT-deficient individuals: a randomised phase 2 study.

ERJ open research·2025
Same author

Liver Characterization of a Cohort of Alpha-1 Antitrypsin Deficiency Patients with and without Lung Disease.

Journal of clinical and translational hepatology·2024
Same author

The influence of body mass index on airway resistance in children with sickle cell disease: A longitudinal study based on impulse oscillometry.

Respiratory medicine·2024
Same author

Testing Patterns and Disparities for Alpha-1 Antitrypsin Deficiency.

The American journal of medicine·2023
Same author

The influence of pediatricians' recommendation on caregivers' COVID-19 vaccine acceptance for children: A nationwide cross-sectional survey study from USA.

Frontiers in pediatrics·2023

Related Experiment Video

Updated: Mar 30, 2026

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.8K

Ivacaftor Therapy in CF Patients: Single Center Experience.

Pritish Mondal1, Amber Loyson1, Jorge Lascano2

  • 1Department of Pediatrics, University of Florida, 1600 SW Archer Road, Suite HD 604, P.O. Box 100296, Gainesville, FL 32610, USA.

Advances in Medicine
|November 12, 2015
PubMed
Summary

Ivacaftor therapy significantly improved lung function and BMI in cystic fibrosis patients with established lung disease. This single-center study showed a 35% mean FEV1 improvement, higher than previously reported.

More Related Videos

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
07:04

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients

Published on: February 11, 2017

20.3K
Standardized Measurement of Nasal Membrane Transepithelial Potential Difference NPD
09:47

Standardized Measurement of Nasal Membrane Transepithelial Potential Difference NPD

Published on: September 13, 2018

17.5K

Related Experiment Videos

Last Updated: Mar 30, 2026

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.8K
Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
07:04

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients

Published on: February 11, 2017

20.3K
Standardized Measurement of Nasal Membrane Transepithelial Potential Difference NPD
09:47

Standardized Measurement of Nasal Membrane Transepithelial Potential Difference NPD

Published on: September 13, 2018

17.5K

Area of Science:

  • Pharmacology
  • Pulmonology
  • Medical Genetics

Background:

  • Ivacaftor, approved in 2012, is the first pharmaceutical targeting cystic fibrosis transmembrane conductance regulator (CFTR) protein function.
  • Cystic fibrosis (CF) is a genetic disorder affecting multiple organs, primarily the lungs.
  • Effective CFTR potentiation is crucial for managing CF.

Purpose of the Study:

  • To report the clinical experience of Ivacaftor in a small cohort of CF patients with established lung disease.
  • To evaluate the efficacy of Ivacaftor in improving lung function and body mass index (BMI) in this specific patient group.
  • To highlight the potential for greater lung function recovery with Ivacaftor in patients with pre-existing lung damage.

Main Methods:

  • A single-center case series involving five patients (four pediatric, one adult) with cystic fibrosis.
  • Assessment of subjective and objective health improvements, including FEV1 (forced expiratory volume in 1 second), FEF25-75, and BMI.
  • Comparison of observed FEV1 improvement with findings from larger studies on Ivacaftor therapy.

Main Results:

  • All five patients experienced both subjective and objective health improvements.
  • Significant increases in FEV1 (mean 35% improvement) and FEF25-75 were observed, alongside BMI gains.
  • The observed FEV1 improvement in patients with established lung disease surpassed the 6.7% mean improvement reported in larger studies with patients having normal lung function.

Conclusions:

  • Ivacaftor can lead to substantial lung function recovery in cystic fibrosis patients with established lung disease.
  • The findings suggest Ivacaftor's efficacy may be more pronounced in patients with compromised lung function.
  • High cost and lifelong therapy necessitate careful consideration and advocacy for patient access.